Maure-Blesa, L, Carmona-Iragui, M, Lott, I, Head, E, Wisniewski, T, Rafii, MS, Espinosa, J, Flórez, J, Mobley, WC, Holland, A, Strydom, A, Zaman, S, Fortea, J. The history of Down syndrome-associated Alzheimer's disease; past, present, and future. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70158. PMID:40469048. IF:11.100(Q1/1D).

Liu, XL, de Boer, SCM, Cortez, K, Poos, JM, Illán-Gala, I, Heuer, H, Forsberg, LK, Casaletto, K, Memel, M, Appleby, BS, Barmada, S, Bozoki, A, Clark, D, Cobigo, Y, Darby, R, Dickerson, BC, Domoto-Reilly, K, Galasko, DR, Geschwind, DH, Ghoshal, N, Graff-Radford, NR, Grant, IM, Hsiung, GYR, Honig, LS, Huey, ED, Irwin, D, Kantarci, K, Léger, GC, Litvan, I, Mackenzie, IR, Masdeu, JC, Mendez, MF, Onyike, CU, Pascual, B, Pressman, P, Bayram, E, Ramos, EM, Roberson, ED, Rogalski, E, Bouzigues, A, Russell, LL, Foster, PH, Ferry-Bolder, E, Masellis, M, van Swieten, J, Jiskoot, L, Seelaar, H, Sanchez-Valle, R, Laforce, R, Graff, C, Galimberti, D, Vandenberghe, R, de Mendonça, A, Tiraboschi, P, Santana, I, Gerhard, A, Levin, J, Sorbi, S, Otto, M, Pasquier, F, Ducharme, S, Butler, CR, Le Ber, I, Finger, E, Rowe, JB, Synofzik, M, Moreno, F, Borroni, B, Boeve, BF, Boxer, AL, Rosen, HJ, Pijnenburg, YAL, Rohrer, JD, Tartaglia, MC. Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia. ALZHEIMERS & DEMENTIA. 2025; 21(4)DOI:10.1002/alz.14608. PMID:40277074. IF:11.100(Q1/1D).

Smith, RG, Pishva, E, Kouhsar, M, Imm, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Altuna, M, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Winchester, L, Nevado-Holgado, A, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Bertram, L, Lunnon, K. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14098. PMID:39193893. IF:11.100(Q1/1D).

Bellver-Sanchis, A, Valle-Garcia, D, Barbaraci, C, Romero-Becerra, F, Singh, RK, Jarne-Ferrer, J, Vasilopoulou, F, Irisarri, A, Martínez-Fernández, C, Fafián-Labora, JA, Arufe, MC, Wüst, C, Castellanos, A, Soto, D, Casals, N, Fadó, R, Pocock, JM, Navarro, G, Val, C, Brea, J, Loza, MI, Lleó, A, Fortea, J, Alcolea, D, Perez-Bosque, A, Miró, L, Pérez, B, Rashid, S, Ali, M, Saqib, M, li Carbó, M, Guerrero, A, Vázquez, S, Choudhary, BS, Dai, SD, Escolano, C, Franco, R, Pallàs, M, Griñán-Ferré, C. First-in-class SAM-competitive G9a inhibitor FLAV-27 as adisease-modifying therapy for Alzheimer disease. MOLECULAR THERAPY. 2026; 34(4)DOI:10.1016/j.ymthe.2025.12.038. PMID:41445192. IF:12.000(Q1/1D).